Devices & Diagnostics

A button-sized implant aims to deliver extended release pain meds for weeks

A small, implantable device being designed to deliver extended-release pain medicine aims to ensure patient compliance and stymie opiate abuse.


A small, implantable device being designed to deliver extended-release pain medicine aims to ensure patient compliance and stymie opiate abuse.

Axxia Pharmaceuticals is developing an implant the size and shape of a shirt button that can subcutaneously deliver an opiate for 30 to 90 days without any moving parts. The first application of the technology will deliver hydromorphone for treatment of moderate to severe chronic pain in cancer patients. CEO Wayne Pollock said the company plans to file an Investigational New Drug application for the implant by the fourth quarter of 2012.

According to the company’s website, it can deliver continuous dosing without an initial burst of the drug upon implantation and without slowing down as the concentration of the drug decreases. The minimally invasive device can also be easily manufactured with different dosages and release durations, and can be implanted and removed by a nurse or physician’s assistant in less than 10 minutes without sutures, the company says.

It’s nonbiodegradable and made from nonallergenic materials that are already approved for use in humans. Hydromorphone, the active ingredient, is a generic but potent pain medication that’s already approved and commonly used to treat patients with cancer-related pain.

In many countries, patients don’t have adequate access to pain medication because of regulations that attempt to control abuse, and Axxia’s website suggests that the company is looking at international markets for its device. BCC valued the global market for pain management drugs and devices at $19 billion in 2008 and estimated it would grow 11.5 percent annually through 2013.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Other novel methods for extended-release delivery of opioids include transdermal patches and an intranasal device being developed by NeuroPharma. Concerns with implanted delivery devices currently on the market include surgery safety, dosing errors, infection and pump inversion. Many of these devices also aren’t designed to deliver opioids, Axxia says.

As disclosed in a recent U.S. Securities and Exchange Commission filing, the Bel Air, Maryland company is currently in the process of raising $800,000.

[Photo from graur razvan ionut]